2017 News

Stay up to date on all that’s happening at Santen USA. For our global headquarters news, visit Santen Worldwide.

News

12.21.2017 Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)

11.01.2017 Santen Consolidated Results for Q2 Fiscal 2017

09.19.2017 Santen Selected as a Member of Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment

08.01.2017 First Quarter Financial Results for the Fiscal Year Ending March 31, 2018

07.25.2017 Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration

05.10.2017 Santen Reports Fiscal 2016 Consolidated Performance

05.01.2017 Santen to Establish a Corporate Venture Capital Fund in the United States

04.25.2017 Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Intravitreal Sirolimus (DE-109) in the Treatment of Non-Infectious Uveitis of the Posterior Segment

04.07.2017 Santen Announces Strategic Investment in Regenerative Patch Technologies LLC ('RPT').

03.02.2017 Santen and Singapore Eye Research Institute (Seri) Announce an Expanded Relationship Including the Creation of a New Joint Laboratory to Develop Novel Ophthalmic Therapeutics, Diagnostics and Devices

Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved